Novo A/S

This profile gathers the share dealings of Novo A/S across 9 companies, led by Tobira Therapeutics, Inc., Reata Pharmaceuticals Inc and Anaptysbio, Inc. Between 2 March 2016 and 14 June 2017, the trades on record add up to 45 filings.

On the open market, the record shows 7 purchases worth €23.8M and 27 sales worth €88.4M. On balance, insiders were net sellers of €64.6M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. So far in 2017, the count stands at 1 purchase and 10 sales.

In size, the median ticket on the buying side is €1.8M. On 6 out of 7 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 4 purchases show a median change of +24.1%, with the price up in 75% of them. They describe history only and say nothing certain about the share price ahead.

Most recently, on 14 June 2017, the filings show an open-market sale worth €259k in Reata Pharmaceuticals Inc. The clock since the last published purchase (1 February 2017) now reads 3,549 days. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.